Molecular biology of exocrine pancreatic cancer

Clinical and Translational Oncology

Volumn 8, Issue 5, 2006, Pages 306-312

  Soto, José Luis ^a   Barbera, Víctor Manuel ^a   Saceda, Miguel ^a   Carrato, Alfredo ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b Elche University Hospital   (Spain)

Author keywords

Genetic alterations; Molecular biology; New drugs; Pancreatic cancer

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CURCUMIN; ERLOTINIB; ETALOCIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; LONAFARNIB; MATUZUMAB; METALLOPROTEINASE INHIBITOR; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PANITUMUMAB; PELITINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ROFECOXIB; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB; TUMOR PROTEIN;

AGE; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG RESPONSE; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS SURGERY; POINT MUTATION; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR VASCULARIZATION; FAMILIAL CANCER; GENE EXPRESSION PROFILING; GENETICS; ONCOGENE; ONCOGENE RAS; PANCREAS TUMOR; TUMOR SUPPRESSOR GENE;

CARCINOMA, PANCREATIC DUCTAL; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM PROTEINS; NEOPLASTIC SYNDROMES, HEREDITARY; ONCOGENES; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 33747503956     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0175-9     Document Type: Review

References (66)

1. Weiderpass E, Partanen T, Kaaks R, et al. Occurrence, trends and environment aetiology of pancreatic cancer. Scand J Work Environ Health. 1998;24(3):165-74.
2. Fryzek JP, Garabrant DH, Greenson JK, Schottenfeld D. A review of the epidemiology and pathology of pancreas cancer. Gastrointest Cancer. 1997;2:99-110.
3. Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer: from genes to families. Surg Oncol Clin N Am. 1998;7:1-23.
4. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia. A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-86.
5. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1-1734.
6. Real FX. Adenocarcinoma: Biología molecular. En: Navarro S, Pérez-Mateo M, Guarner L, eds. Tratado de Páncreas Exocrino. Barcelona: J&C Ediciones Médicas, S.L.; 2002. p. 347-55.
7. Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet. 2003;4:237-56.
8. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
9. Smit VT, Boot AJ, Smits AM, et al. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988;16:7773-82.
10. Grünewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer. 1989;43:1037-41.
11. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545-54.
12. Berrozpe G, Schaeffer J, Peinado MA, et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer. 1994;58:185-91.
13. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994; 54:5568-73.
14. Finkelstein SD, Przygodzki R, Pricolo VE, et al. K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch Surg. 1994; 129:567-72.
15. Scarpa A, Capelli P, Villanueva A, et al. Pancreatic cancer in Europe: Ki-ras mutation pattern shows geographical differences. Int J Cancer. 1994;57:167-71.
16. Malats N, Porta M, Corominas JM, et al. Ki-ras mutations in exocrine pancreatic cancer: Association with clinico-pathological characteristics and with tobacco and alcohol consumption. PANK-ras 1 Project Investigators. Int J Cancer. 1997;70(6):661-7.
17. Yanagisawa A, Ohtake K, Ohashi K, et al. Frequent c-ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer. Res 1993;53:953-6.
18. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutations in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology. 1996;110:227-31.
19. Lüttges J, Schlehe B, Menke MA, et al. The K-ras mutations pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer. 1999;85(8):1703-10.
20. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57:2140-3.
21. Terhune PG, Phifer DM, Tosteson TD, et al. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol Biomarkers Prev. 1998;7(6):515-21.
22. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur J Cancer. 2005;41:2213-36.
23. Porta M, Malats N, Guarner L, et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. J Epidemiol Community Health. 1999;53:702-9.
24. Porta M, Malats N, Jariod M, et al. Serum levels of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet. 1999;354:2125-9.
25. Greenblatt M, Bennett W, Holistein M, Hards C. Mutations in the p53 tumor suppressor gene clues to cancer aetiology and molecular pathogenesis. Cancer Res. 1994;54:4855-78.
26. Kalthoff H, Schmiegel W, Roeder C, et al. P55 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene. 1993;8:289-98.
27. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 1993; 142:1534-43.
28. Boschman CR, Stryker S, Reddy JK, Rao MS. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. Am J Pathol. 1994;145:1291-5.
29. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994;54:3025-33.
30. Rall ChJ, Yan YX, Graeme-Cook F, et al. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas. 1996;12(1):10-7.
31. Li Y, Bhuiyan M, Vaitkevicius VK, Sarkar FH. Molecular analysis of the p53 gene in pancreatic adenocarcinoma. Diagn Mol Pathol. 1998;7(1):4-9.
32. Hoshi T, Imai M, Ogawa K, et al. Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. J Surg Oncol. 1994;55:84-91.
33. Weyrer K, Feichtinger H, Haun M, et al. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest. 1996;74:279-89.
34. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-30.
35. Sasaki S, Yamamoto H, Kaneto H, et al. Differential roles of alterations of p53, p16 and SMA D4 expression in the progression of intraductal papillary-mucinous tumours of the pancreas. Oncol Rep. 2003;10(1):21-5.
36. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527-30.
37. Hahn SA, Hoque ATMS, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996a; 56:490-4.
38. Hahn SA, Schutte M, Shamsul Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996b;271:350-4.
39. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for DPC4 mirrors genetic status in pancreatic adenocarcinomas. A new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-45.
40. Miwa W, Yasuda J, Murakami Y, et al. Isolation of DNA sequences amplified at chromosome 19q13.1-13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun. 1996;225:968-74.
41. Cheng JQ, Ruggery B, Klein WN, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Nat Acad Sci. 1996;93:3636-41.
42. Curtis LJ, Li Y, Gerbault-Seureau M, et al. Amplification of DNA sequences from chromosomes 19q13.1 in human pancreatic cell lines. Genomics. 1998;53(1):42-55.
43. Wallrapp C, Müller-Pillasch F, Solinas-Toldo S, et al. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 1997;57:3135-9.
44. Barton CM, McKie AB, Hogg B, et al. Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in pancreatic adenocarcinoma. Mol Carcinog. 1995;13:61-9.
45. Weger AR, Falkmer UG, Schwab G, et al. Nuclear DNA distribution pattern of the parenchymal cells in adenocarcinomas of the pancreas and in chronic pancreatitis. Gastroenterology. 1990;99:237-42.
46. Porschen R, Remy U, Bevers G, et al. Prognostic significance of DNA ploidy in adenocarcinoma of the pancreas. A flow cytometric study of paraffin-embedded specimens. Cancer. 1993;71(12):5846-50.
47. Weyrer K, Feichtinger H, Haun M, et al. p55, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest. 1996;74:279-89.
48. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 2001; 61:8540-6.
49. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60(7):1835-9.
50. Fukushima N, Sato N, Ueki T, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 2002;160(5): 1573-81.
51. Friess H, Guo XZ, Nan BC, Kleef O, Buchler MW. Growth factors and cytokines in pancreatic carcinogenesis. Ann N Y Acad Sci. 1999;880:110-21.
52. Yonemash H, Takashima M, Nishiyama KI, et al. Phenotypical characteristics of undifferentiated carcinoma of the pancreas: A comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, alpha catenin and beta catenin expression. Oncol Rep. 2001;4:745-52.
53. Bramhall SR. The Matrix Metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol. 1997;21(1):1-12.
54. Logsdon CD, Simeone DM, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63(10):649-57.
55. Iacobuzio-Donahue CA, Maitra A, Olsen M, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2005;162(4):1151-62.
56. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2005;63(13):5735-42.
57. Friess H, Ding J, Kleeff J, et al. Microarray -based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci. 2003;60(6):1180-99.
58. Hahn SA, Kartstch DK. Genetics of hereditary pancreatic carcinoma. Gastroenterol Clin N Am. 2004;33:919-34.
59. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001;7(3):738-44.
60. Schutte M, da Costa LT, Hahn SA, et al. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within BRCA2 region. Proc Natl Acad Sci USA. 1995;92:5950-1.
61. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003; 95(3):214-21.
62. Van Cutsem E, Van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared to gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-8.
63. Bramhall SR, Schulz J, Nemunaitis J, et al. A double blind placebo controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-7.
64. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004;22:2610-6.
65. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trial Group (NCIC-CTG)-Proc 2005 Gastrointestinal Cancers Symposium, Orlando, FL, January 27-29, 2005 (abstr 77).
66. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-40.